



Theratechnologies raises additional gross proceeds of \$1.35 million through exercise of over-allotment option

Not for distribution to U.S. news wire services or dissemination in the United States.

Montréal, April 20th, 2006 - Theratechnologies Inc. (TSX: TH) announced today that following the successful issue of 10,500,000 common shares for gross proceeds of \$20,475,000 on March 21, 2006, the syndicate of underwriters led by BMO Nesbitt Burns has exercised the over-allotment option granted to them in connection with the offering and has purchased 692,500 additional common shares for gross proceeds of \$1,350,375. The closing of this transaction today brings the total gross proceeds of the offering to \$21,825,375.

The net proceeds of the offering, including the over-allotment portion are being used to finance Theratechnologies' research and development expenditures (mainly the two Phase 3 clinical studies for TH9507 in HIV-associated lipodystrophy) and additional working capital requirements.

The securities offered have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets. The most advanced program is in Phase 3 clinical development in HIV-associated lipodystrophy, a serious metabolic complication. The Company also has other promising projects at various stages of development.

Additional information about Theratechnologies

Further information relating to Theratechnologies is available on the Company's website at <http://www.theratech.com>. Additional information, including the Company's Annual Information Form, is available on SEDAR at www.sedar.com.

###

Contact:

Luc Tanguay
Senior Vice President & Chief Financial Officer
Phone: (514) 336-4804, ext. 204
Email: ltanguay@theratech.com

Theratechnologies Inc.

2310 Alfred-Nobel Blvd., Saint Laurent, Québec, Canada H4S 2A4

Phone: (514) 336-7800 • Fax: (514) 336-7242 • www.theratech.com • thera@theratech.com

Tobie Trudel
Director, Investor Relations
and Communications
Phone: (514) 336-4804, ext. 229
Email: trudel@theratech.com